AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, will be presented at the American Society of Clinical Oncology’s 2024 Gastrointestinal Cancers Symposium (ASCO GI), taking place January 18 – 20, 2024 in San Francisco, California. Natera and its collaborators will present 11 abstracts that feature new Signatera data across various GI in ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury has reached a verdict in the United States District Court for the Western District of Texas regarding a patent infringement lawsuit brought by Ravgen, Inc. against Natera. Natera noted that the damages award of $57 million was significantly less than the $410 million Ravgen was seeking. In addition, the jury determined there was no willful infringement by Natera. This decision ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced preliminary revenue results for the fourth quarter and full year ended Dec. 31, 2023. The Company expects the following: Total revenues of approximately $300 million in the fourth quarter of 2023, an increase of approximately 38% compared to $217 million in the fourth quarter of 2022. Total revenues of approximately $1.07 billion in 2023, an increase of approximately 30% compare ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, Jan. 9, 2024 at 3:45 p.m. PT (6:45 p.m. ET). Members of Natera’s management will deliver a presentation and host a Q&A with the investment community at the conference. A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.co ...

red_moon_rise/E+ via Getty Images Executive Summary The journey to bring molecular non-invasive prenatal screening/testing 'NIPT' to mainstream healthcare standards hasn't been easy. The sector faced and overcame the challenges of proving the accuracy and reliability of this tech. Natera (NASDAQ:NTRA) offers an opportunity to capitalize on the considerable groundwork already laid as we enter an era of widespread acceptance for all pregnant women, regardless of age, leveraging the established trust and ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. The full study can be found here. To date, mVAF and MTM/mL are the two main metrics th ...

Investor presentation × × × × × × × × × × × × × × × × × Ｘ Ｘ x × × × × × × × Ｘ Ｘ × Ｘ Ｘ × X × × × × × × × These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred ...

Table of Contents FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Commission file number: 001-37478 NATERA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 01-0894487 (State or O ...

Natera, Inc. × × × × × × × × × × × × × × × × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ × × × × × × × × Ｘ Ｘ × × × × X X Safe harbor statement X × natera® Second Quarter 2023 Earnings Call August 3, 2023 × × × × × × × × × × Ⅹ Ｘ Ｘ Ｘ Ｘ Ｘ X X × × × × Ｘ Ｘ × × × x X X X × X X × × × × × Ｘ Ｘ × × × × × × × × × × Investor presentation × × × × 2 × × × × × These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and chal ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 32% year-on-year, reaching a total of $1.025 billion for the year, with a sequential increase of 8% from the previous quarter [5][11] - Gross margin improved to just above 45%, up from 39% in Q1, attributed to continued improvements in cost of goods sold (COGS) [5][22] - The company achieved a significant reduction in quarterly cash burn, projecting an annual reduction of approximately $150 million [5][56] Business Line Data and Key Metrics Changes - In women's health, volumes increased by over 23% year-on-year, with strong performance from the Panorama test, which is supported by the SMART study [5][17][25] - The oncology segment saw a substantial increase in test volumes and average selling prices (ASPs), particularly for the Signatera test, which nearly doubled in size year-on-year [19][41] - The company noted a shift in volume back to Panorama in California, positively impacting both margin and revenue [23] Market Data and Key Metrics Changes - The company highlighted strong growth in the oncology market, particularly in the context of Medicare reimbursement for Signatera, which is expected to drive further adoption [19][41] - The market for expanded carrier screening is anticipated to grow as coverage improves, with the company optimistic about future reimbursement rates [31][57] Company Strategy and Development Direction - The company is focused on enhancing its leadership in data generation and clinical validation, with ongoing trials and publications supporting its products [12][41] - There is a commitment to improving margins in women's health by optimizing product offerings and reducing lower-margin volumes [18][24] - The company aims to leverage its first-mover advantage in oncology and expand its presence in breast cancer through ongoing studies and partnerships [51][53] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial goals for the year, citing strong execution and operational leverage [11][56] - The company is well-positioned to navigate changes in the regulatory environment, with a focus on maintaining high-quality, peer-reviewed products [77] - Management noted that while there are temporary drags on gross margins due to strategic initiatives, the long-term outlook remains positive [66][70] Other Important Information - The company recently won significant litigation cases, including a $19.35 million award in a patent infringement lawsuit, which could enhance its competitive position [15] - The company is actively engaging with private payers to expand coverage for its tests, particularly in light of legislative changes [85] Q&A Session Summary Question: What is the outlook for gross margins in the reproductive health business? - Management indicated that while there were one-time events affecting margins, they expect continued improvement as initiatives take effect [58][66] Question: What proportion of oncologists are exclusively using Signatera for MRD? - Management reported high account retention rates, indicating that once oncologists adopt Signatera, they are less likely to switch to competitors [68][70] Question: Can you provide updates on ASP trends within the women's health business? - Management noted that ASPs are expected to improve through better billing operations and early coverage for expanded carrier screening [73][76] Question: How is the company preparing for potential regulatory changes from the FDA? - Management emphasized their thorough validation of tests and extensive peer-reviewed publications, positioning them well for any regulatory changes [77] Question: What is the current penetration of NIPT and its expected growth? - Management stated that NIPT is currently around 50% penetrated, with expectations to reach 80-85% over the next few years [102]